|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (EMA (2017), FDA (2018)) |
IUPAC Name ![]() |
2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile |
International Nonproprietary Names ![]() |
|
INN number | INN |
9570 | baricitinib |
Synonyms ![]() |
INCB-028050 | INCB028050 | LY-3009104 | LY3009104 | Olumiant® |
Comments |
Baricitinib is a JAK1 and 2 selective inhibitor. The compound is orally bioavailable. |
Database Links ![]() |
|
CAS Registry No. | 1187594-09-7 |
ChEMBL Ligand | CHEMBL2105759 |
GtoPdb PubChem SID | 223366123 |
PubChem CID | 44205240 |
RCSB PDB Ligand | 3JW |
Search Google for chemical match using the InChIKey | XUZMWHLSFXCVMG-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | XUZMWHLSFXCVMG |
Search PubMed clinical trials | baricitinib |
Search PubMed titles | baricitinib |
Search PubMed titles/abstracts | baricitinib |
Search UniChem for chemical match using the InChIKey | XUZMWHLSFXCVMG-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | XUZMWHLSFXCVMG |
Wikipedia | Baricitinib |